Pharma News

27 October 2025

Innovent's Mazdutide Shows Superiority in Glycemic Control with Weight Loss over Semaglutide

Innovent Biologics, Inc., a leading biopharmaceutical company focused on developing and commercializing high-quality medicines, announced that its fourth Phase 3 clinical trial, DREAMS-3, evaluating mazdutide, a dual glucagon-like peptide-1 (GLP-1) and glucagon (GCG) receptor agonist met its primary endpoint.

27 October 2025

Dr Reddy’s to Launch Generic Version of Wegovy in 87 Countries Next Year

Dr Reddys Laboratories Ltd, one of Indias leading pharmaceutical companies, plans to launch a lower-cost generic version of Novo Nordisks blockbuster weight-loss drug Wegovy across 87 countries next year, according to the company’s Chief Executive Officer, Erez Israeli.

27 October 2025

Blenrep approved by USFDA for use in treatment of relapsed/refractory multiple myeloma

GSK plc announced the US Food and Drug Administration (FDA) has approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone (BVd) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory (IMID) agent.

26 October 2025

Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline

Avidity is committed to delivering a new class of pioneering RNA therapeutics called Antibody Oligonucleotide Conjugates for serious, genetic neuromuscular diseases. The proposed acquisition will bring Aviditys late-stage neuroscience programs into Novartis and provide Novartis access to a differentiated RNA-targeting delivery platform.

23 October 2025

Biocon Biologics receives approval of Psoriasis biosmilar in Canada

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd., announced that Health Canada has granted a Notice of Compliance (NOC) for Yesintek™ (ustekinumab injection) and Yesintek™ I.V., a biosimilar to Stelara® (ustekinumab injection) and Stelara® I.V. (ustekinumab for injection, solution for intravenous infusion). The approval was granted on October 17, paving the way for Canadian commercial availability in mid-October.

23 October 2025

Cipla got permission to sell Lilly's weight loss medicine

Eli Lilly and Cipla Limited announced an agreement to distribute and promote tirzepatide in India under a second brand name, Yurpeak

15 October 2025

Lilly's Oral GLP-1, Orforglipron, Demonstrated Superior Glycemic Control in Two Successful Phase 3 Trials

Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 ACHIEVE-2 and ACHIEVE-5 trials. ACHIEVE-2, the second head-to-head trial in the program, evaluated orforglipron versus dapagliflozin, an SGLT-2 inhibitor, in adults with type 2 diabetes inadequately controlled on metformin.

15 October 2025

Molecular markers and risk models guide precision care in liver cancer surgery

Liver cancer remains one of the worlds most lethal cancers, ranking as the third leading cause of cancer-related deaths. Although surgical advances have improved safety, recurrence after hepatectomy continues to be a major challenge.

15 October 2025

Ateneo scientists research potential anti-ulcer vaccine

Since ancient times, it was thought that painful stomach ulcers were caused by eating spicy foods or having an unhealthy diet. But since then, researchers have found that Helicobacter pylori a common bacterium found in over 60% of the world’s population—was the real culprit behind most stomach ulcers and a high risk for stomach cancer.

14 October 2025

AstraZeneca Reaches Landmark Agreement with Trump Administration to Cut U.S. Drug Prices, Invest 50 Billion USD in Domestic Manufacturing

AstraZeneca has announced a historic agreement with President Donald J. Trump’s administration to reduce the cost of prescription medicines for American patients while maintaining the nation’s leadership in biopharmaceutical innovation.

At a White House event, AstraZeneca CEO Pascal Soriot joined President Trump and senior officials to confirm that the company has voluntarily met all four requests outlined in the President’s July 31 letter. The agreement enables American patients to access AstraZeneca medicines at prices aligned with those in other wealthy nations.

Search

Innovent's Mazdutide Shows Superiority in Glycemic Control with Weight Loss over Semaglutide

RECOMMENDED POSTS

Subscribe with us

Jobs by Category